Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budesonide + formoterol fumarate
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
BFF (PT009) is a fixed-dose combination of budesonide and formoterol fumarate delivered via a pressurized metered-dose inhaler (pMDI) using AstraZeneca's proprietary Aerosphere delivery technology. This technology utilizes porous phospholipid particles to create a stable co-suspension, ensuring uniform drug delivery and consistent dosing. Budesonide is an inhaled corticosteroid (ICS) that reduces airway inflammation by activating glucocorticoid receptors, while formoterol fumarate is a long-acting beta2-agonist (LABA) that induces bronchodilation by stimulating beta-2 adrenergic receptors. Developed by AstraZeneca (following the acquisition of Pearl Therapeutics), BFF is primarily indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently being evaluated in Phase III trials, such as the VATHOS study, to compare its efficacy and safety against budesonide monotherapy and other established formulations like the Symbicort Turbuhaler.
- Brand names
- Symbicort Aerosphere
- Other names
- Budesonide/Formoterol Fumarate AerosphereBudesonide/Formoterol Fumarate MDI
02
Targets
AC (Adenylyl cyclase family)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)ADRB1 (β1)ADRB2 (β2)
Beyond the preview
Go deeper on budesonide + formoterol fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budesonide + formoterol fumarate.